These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24845945)

  • 61. Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.
    Delaunois A; Abernathy M; Anderson WD; Beattie KA; Chaudhary KW; Coulot J; Gryshkova V; Hebeisen S; Holbrook M; Kramer J; Kuryshev Y; Leishman D; Lushbough I; Passini E; Redfern WS; Rodriguez B; Rossman EI; Trovato C; Wu C; Valentin JP
    Clin Transl Sci; 2021 May; 14(3):1133-1146. PubMed ID: 33620150
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.
    Turner JR; Rodriguez I; Mantovani E; Gintant G; Kowey PR; Klotzbaugh RJ; Prasad K; Sager PT; Stockbridge N; Strnadova C;
    J Clin Pharmacol; 2018 Aug; 58(8):997-1012. PubMed ID: 29672845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.
    Picard S; Goineau S; Guillaume P; Henry J; Hanouz JL; Rouet R
    Cardiovasc Toxicol; 2011 Dec; 11(4):285-307. PubMed ID: 21805209
    [TBL] [Abstract][Full Text] [Related]  

  • 64. QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes.
    Meyer T; Leisgen C; Gonser B; Günther E
    Assay Drug Dev Technol; 2004 Oct; 2(5):507-14. PubMed ID: 15671648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolution of mathematical models of cardiomyocyte electrophysiology.
    Amuzescu B; Airini R; Epureanu FB; Mann SA; Knott T; Radu BM
    Math Biosci; 2021 Apr; 334():108567. PubMed ID: 33607174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.
    Authier S; Pugsley MK; Troncy E; Curtis MJ
    J Pharmacol Toxicol Methods; 2010; 62(2):83-8. PubMed ID: 20601020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
    Sala L; Bellin M; Mummery CL
    Br J Pharmacol; 2017 Nov; 174(21):3749-3765. PubMed ID: 27641943
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.
    Stoelzle S; Haythornthwaite A; Kettenhofen R; Kolossov E; Bohlen H; George M; Brüggemann A; Fertig N
    J Biomol Screen; 2011 Sep; 16(8):910-6. PubMed ID: 21775699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety pharmacology methods and models in an evolving regulatory environment.
    Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Benchmarking safety pharmacology regulatory packages and best practice.
    Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
    J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of Ion Currents Components Generating Field Potential Recorded in MEA From hiPSC-CM.
    Raphel F; Boulakia M; Zemzemi N; Coudiere Y; Guillon JM; Zitoun P; Gerbeau JF
    IEEE Trans Biomed Eng; 2018 Jun; 65(6):1311-1319. PubMed ID: 28880155
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
    Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In-silico human electro-mechanical ventricular modelling and simulation for drug-induced pro-arrhythmia and inotropic risk assessment.
    Margara F; Wang ZJ; Levrero-Florencio F; Santiago A; Vázquez M; Bueno-Orovio A; Rodriguez B
    Prog Biophys Mol Biol; 2021 Jan; 159():58-74. PubMed ID: 32710902
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations.
    Gintant G; Kaushik EP; Feaster T; Stoelzle-Feix S; Kanda Y; Osada T; Smith G; Czysz K; Kettenhofen R; Lu HR; Cai B; Shi H; Herron TJ; Dang Q; Burton F; Pang L; Traebert M; Abassi Y; Pierson JB; Blinova K
    Regul Toxicol Pharmacol; 2020 Nov; 117():104756. PubMed ID: 32822771
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [hiPSCs and organoids: prediction of arrhythmogenic risks for optimized traditional Chinese medicine].
    Sun HK; Gao Y; Zhu MJ; Tang JF; Wu Y; Li B; Yu R; Wang Y; Zhou LY
    Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(20):5404-5409. PubMed ID: 38114134
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms.
    Pfeiffer-Kaushik ER; Smith GL; Cai B; Dempsey GT; Hortigon-Vinagre MP; Zamora V; Feng S; Ingermanson R; Zhu R; Hariharan V; Nguyen C; Pierson J; Gintant GA; Tung L
    J Pharmacol Toxicol Methods; 2019; 99():106612. PubMed ID: 31319140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.